Lantheus Secures FDA Nod for BRAVNETSA, First Radiopharmaceutical via ANDA Pathway
Event summary
- Lantheus received final FDA approval for BRAVNETSA (lutetium Lu 177 dotatate) on September 22, 2026, the first radiopharmaceutical approved via the ANDA pathway.
- BRAVNETSA is bioequivalent and therapeutically equivalent to LUTATHERA® for treating somatostatin receptor-positive GEP-NETs.
- The approval marks Lantheus' expansion into radioligand therapies, targeting a U.S. patient population of approximately 200,000 with GEP-NETs.
- Lantheus aims to ensure reliable supply and broad patient access through a 'thoughtful launch' strategy.
The big picture
Lantheus' FDA approval for BRAVNETSA via the ANDA pathway is a strategic milestone, opening a new regulatory route for radiopharmaceuticals. The move positions Lantheus as a direct competitor to Novartis' LUTATHERA in the GEP-NETs market, which has seen rising prevalence and diagnostic challenges. The approval underscores the growing importance of radioligand therapies in oncology treatment.
What we're watching
- Market Adoption
- Whether Lantheus can achieve broad adoption of BRAVNETSA against established competitors like LUTATHERA.
- Supply Chain
- The pace at which Lantheus can scale production to meet demand for BRAVNETSA.
- Regulatory Pathway
- How this ANDA approval may influence future radiopharmaceutical approvals.